Cryoport Q3 net loss widens 56% to $10.85 million; Q3 revenue rises 14% to $50.22 million

Bitget2026/11/05 21:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cryoport’s third-quarter 2026 net loss widened 56% year-over-year to $10.85 million.
Revenue rose 14% year-over-year to $50.22 million, including Life Sciences Services revenue of $28.56 million, up 18%.
The business supported 788 clinical trials worldwide and 23 commercially approved cell and gene therapies at September 30, 2026.
Full-year 2026 revenue guidance increased to a range of $197 million to $199 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryoport Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051605PR_NEWS_USPR_____LA90523) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cryoport Q3 net loss widens 56% to $10.85 million; Q3 revenue rises 14% to $50.22 million

You may also like

Crypto prices